Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179081 | 0.99 | ESR1 (0.68) | ESR1ESR2ALOX5ALDH1A1MAPT | |
| SCHEMBL3178718 | 0.97 | ESR1 (0.67) | ESR1ESR2ALOX5ALDH1A1MAPT | |
| SCHEMBL3176317 | 0.93 | ESR1 (0.58) | ESR1ESR2ALOX5ALDH1A1MAPT | |
| SCHEMBL3171859 | 0.90 | ESR1 (0.54) | ESR1ESR2ALOX5ALDH1A1MAPT | |
| SCHEMBL3168847 | 0.89 | ESR1 (0.85) | ESR1ESR2 | |
| SCHEMBL3168858 | 0.89 | ESR1 (0.85) | ESR1ESR2 | |
| SCHEMBL3163197 | 0.88 | ESR1 (0.85) | ESR1ESR2 | |
| SCHEMBL3163205 | 0.88 | ESR1 (0.85) | ESR1ESR2 | |
| SCHEMBL3181197 | 0.87 | ESR1 (0.76) | ESR1ESR2ALDH1A1MAPT | |
| SCHEMBL3170191 | 0.86 | ESR1 (0.76) | ESR1ESR2ALOX5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649093-B2 | (2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propenoic acid; menopausal or postmenopausal disorders, vasomotor symptoms, vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depression, diabetes, osteoporosis | Glaxo Smith Kline LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-11-29 | — | — | US | disclosed |
| EP-1773750-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002185-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ALOX5 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.